M Garzotto

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. doi request reprint Advances in the multimodality management of high-risk prostate cancer
    Mark Garzotto
    Department of Urology, Portland Veterans Administration Medical Center, Oregon Health and Science University, Portland, OR 97239, USA
    Surg Oncol Clin N Am 22:375-94. 2013
  2. ncbi request reprint Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer
    Mark Garzotto
    Urology Section, Surgical Service, Portland VA Medical Center, Portland, OR 97239, USA
    Urol Oncol 24:254-9. 2006
  3. ncbi request reprint Improved detection of prostate cancer using classification and regression tree analysis
    Mark Garzotto
    Urology Section, Division of Urology, Portland Veterans Administration Medical Center, 3710 SW US Veterans Hospital Rd, Portland, OR 97239, USA
    J Clin Oncol 23:4322-9. 2005
  4. ncbi request reprint Combined androgen deprivation with radiotherapy for prostate cancer: does it make sense?
    M Garzotto
    Urology Section, Portland Veterans Administration Medical Center, Portland, Oregon 97201, USA
    Mol Urol 4:209-13;discussion 215. 2000
  5. ncbi request reprint Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies
    Mark Garzotto
    Urology Section, Portland Veterans Administration Medical Center, Portland, Oregon 97239, USA
    Cancer 104:1911-7. 2005
  6. doi request reprint Contemporary management of high-risk localized prostate cancer
    Mark Garzotto
    Division of Urology, Department of Surgery, and the Department of Radiation Medicine, Oregon Health and Science University, Portland Veterans Administration Medical Center, Portland, OR, 97239, USA
    Curr Urol Rep 11:159-64. 2010
  7. pmc Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer
    T M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Mail Code CR145, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Br J Cancer 91:1425-7. 2004
  8. ncbi request reprint Weekly high-dose calcitriol and docetaxel in advanced prostate cancer
    T M Beer
    Department of Medicine, Oregon Health Sciences University and the Portland Veterans Affairs Medical Center, Portland, OR 97201, USA
    Semin Oncol 28:49-55. 2001
  9. ncbi request reprint Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort
    M el-Geneidy
    Oregon Health and Science University, Department of Medicine, Division of Hematology and Medical Oncology, Oregon, USA
    BJU Int 93:510-5. 2004
  10. ncbi request reprint Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells
    J Dai
    Department of Urology, Urological Oncology Research Laboratory, Joan and Stanford I. Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 7:1370-7. 2001

Collaborators

Detail Information

Publications43

  1. doi request reprint Advances in the multimodality management of high-risk prostate cancer
    Mark Garzotto
    Department of Urology, Portland Veterans Administration Medical Center, Oregon Health and Science University, Portland, OR 97239, USA
    Surg Oncol Clin N Am 22:375-94. 2013
    ..The combination of early cancer detection and technical improvements in local treatment has led to a reduction in disease burden and an increase in cancer survivorship. However, treatment failure remains common among high-risk cases...
  2. ncbi request reprint Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer
    Mark Garzotto
    Urology Section, Surgical Service, Portland VA Medical Center, Portland, OR 97239, USA
    Urol Oncol 24:254-9. 2006
    ..The goal of this phase I/II study is to evaluate the safety and efficacy of neoadjuvant docetaxel and mitoxantrone before prostatectomy...
  3. ncbi request reprint Improved detection of prostate cancer using classification and regression tree analysis
    Mark Garzotto
    Urology Section, Division of Urology, Portland Veterans Administration Medical Center, 3710 SW US Veterans Hospital Rd, Portland, OR 97239, USA
    J Clin Oncol 23:4322-9. 2005
    ..To build a decision tree for patients suspected of having prostate cancer using classification and regression tree (CART) analysis...
  4. ncbi request reprint Combined androgen deprivation with radiotherapy for prostate cancer: does it make sense?
    M Garzotto
    Urology Section, Portland Veterans Administration Medical Center, Portland, Oregon 97201, USA
    Mol Urol 4:209-13;discussion 215. 2000
    ..Thus, paradoxically, AD may reduce the radiosensitivity of prostate cancer by means of cell-cycle delay, which results in a reduction in postmitotic apoptosis...
  5. ncbi request reprint Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies
    Mark Garzotto
    Urology Section, Portland Veterans Administration Medical Center, Portland, Oregon 97239, USA
    Cancer 104:1911-7. 2005
    ..The current study was performed to identify risk factors and risk groups for carcinoma detection in men undergoing repeat prostate biopsies...
  6. doi request reprint Contemporary management of high-risk localized prostate cancer
    Mark Garzotto
    Division of Urology, Department of Surgery, and the Department of Radiation Medicine, Oregon Health and Science University, Portland Veterans Administration Medical Center, Portland, OR, 97239, USA
    Curr Urol Rep 11:159-64. 2010
    ..It is likely that the development of effective strategies based on understanding prostate tumor biology will lead to significant advances in the treatment of this disease...
  7. pmc Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer
    T M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Mail Code CR145, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Br J Cancer 91:1425-7. 2004
    ..Intermittent chemotherapy for AIPC is feasible and deserves further study...
  8. ncbi request reprint Weekly high-dose calcitriol and docetaxel in advanced prostate cancer
    T M Beer
    Department of Medicine, Oregon Health Sciences University and the Portland Veterans Affairs Medical Center, Portland, OR 97201, USA
    Semin Oncol 28:49-55. 2001
    ..Treatment has been well tolerated, with 1 patient experiencing a self-limited grade 3 toxicity and no patients experiencing grade 4 or 5 toxicities...
  9. ncbi request reprint Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort
    M el-Geneidy
    Oregon Health and Science University, Department of Medicine, Division of Hematology and Medical Oncology, Oregon, USA
    BJU Int 93:510-5. 2004
    ..To identify predictors of delayed therapy with curative intent, an increasingly common option in contemporary patients with prostate cancer who initially choose watchful waiting...
  10. ncbi request reprint Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells
    J Dai
    Department of Urology, Urological Oncology Research Laboratory, Joan and Stanford I. Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 7:1370-7. 2001
    ..These data show that NEP can inhibit PC cell growth and tumorigenicity and suggest that NEP has potential as therapy for androgen-independent PC...
  11. pmc Intermittent chemotherapy in metastatic androgen-independent prostate cancer
    T M Beer
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Mail Code L586, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Br J Cancer 89:968-70. 2003
    ..Chemotherapy holiday was associated with an improvement of fatigue (P=0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study...
  12. pmc Erythrocyte fatty acids and prostate cancer risk: a comparison of methods
    J Shannon
    Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239 3098, USA
    Prostaglandins Leukot Essent Fatty Acids 83:161-9. 2010
    ..We provide an example of modeling FA and their inter-relationships on the risk of prostate cancer. Comparing three approaches suggests the importance of considering the impact of the entire fatty acid profile in disease prevention...
  13. ncbi request reprint Current concepts in risk factor assessment for advanced germ cell cancer
    M Garzotto
    Urology Section, Portland Veterans Administration Medical Center Urology Division, USA
    Semin Urol Oncol 19:165-9. 2001
    ..The development of this system has allowed for valid comparisons of ongoing and future trials. Furthermore, this system will serve to encourage international collaboration for the study of high-risk GCT...
  14. ncbi request reprint Effect of calcitriol on prostate-specific antigen in vitro and in humans
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Clin Cancer Res 12:2812-6. 2006
    ..We examined the effects of calcitriol at similar concentration on cell proliferation, androgen receptor (AR) expression, and PSA production in vitro and on PSA concentrations in prostate cancer patients...
  15. ncbi request reprint Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice
    Xi Zheng
    Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway 08854, USA
    Clin Cancer Res 12:3444-51. 2006
    ..To investigate the effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate cancer cells cultured in vitro or grown as tumors in immunodeficient mice...
  16. ncbi request reprint Testosterone loss and estradiol administration modify memory in men
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
    J Urol 175:130-5. 2006
    ..We characterized the impact of androgen deprivation and of subsequent estradiol therapy on the long-term and working memory of patients with prostate cancer...
  17. ncbi request reprint Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Mail Code CR 145, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Cancer Chemother Pharmacol 59:581-7. 2007
    ..DN-101 is a new, high-dose, oral formulation of calcitriol under investigation for the treatment of cancer. We sought to evaluate the tolerability and pharmacokinetics (PK) of weekly doses of DN-101 in patients with advanced cancer...
  18. ncbi request reprint Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?
    Jennifer L Lycette
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    Clin Genitourin Cancer 5:198-205. 2006
    ....
  19. ncbi request reprint Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study
    Julie N Graff
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    J Urol 177:1307-12. 2007
    ..We determined which demographic and clinical factors predict overall and cancer specific survival with this treatment strategy in patients enrolled in the Prostate Cancer Outcomes Study...
  20. ncbi request reprint Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy
    Stephen E F Spurgeon
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
    Urology 69:931-5. 2007
    ..We hypothesized that the prebiopsy PSA doubling time (PSADT) and PSA velocity (PSAV) could predict for cancer detection in a referral population with a suspicion of prostate cancer...
  21. ncbi request reprint Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer
    R Bruce Montgomery
    Department of Medicine, Veterans Affairs Puget Sound Health Care System VAPSHCS, and University of Washington School of Medicine, Seattle, WA 98108, USA
    Cancer 110:996-1002. 2007
    ..The addition of diethylstilbestrol to docetaxel modified tubulin composition and improved the response of prostate cancer to chemotherapy in preclinical models. An attempt was made to recapitulate the observations in a clinical trial...
  22. doi request reprint Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer
    Bruce Montgomery
    Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, Washington 98109, USA
    Urology 72:474-80. 2008
  23. ncbi request reprint Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer
    Daniel M Janoff
    Division of Urology, Oregon Health and Science University and Portland VA Medical Center, Oregon 97239, USA
    BJU Int 96:503-7. 2005
    ....
  24. ncbi request reprint High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study
    Natasha M Tiffany
    Division of Hematology and Medical Oncology, Oregon Health Sciences University and Portland Veterans Affairs Medical Center, Portland 97239, USA
    J Urol 174:888-92. 2005
    ....
  25. ncbi request reprint Statins and prostate cancer risk: a case-control study
    Jackilen Shannon
    Oregon Health and Sciences University, Portland, OR 97239 3098, USA
    Am J Epidemiol 162:318-25. 2005
    ..24, 95% confidence interval: 0.11, 0.53). The results of this case-control study suggest that statins may reduce the risk of total prostate cancer and, specifically, more aggressive prostate cancer...
  26. ncbi request reprint Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer
    Tomasz M Beer
    Oregon Health and Science University and Portland VA Medical Center, Portland, OR 97239, USA
    J Clin Oncol 21:123-8. 2003
    ....
  27. ncbi request reprint Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Urology 63:342-7. 2004
    ..To determine the efficacy of the gonadotropin-releasing hormone antagonist abarelix in patients with androgen-independent prostate cancer progressing after orchiectomy and to measure its effect on serum follicle-stimulating hormone (FSH)...
  28. ncbi request reprint Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL
    Mark Garzotto
    Division of Urology, Portland Veterans Administration Medical Center, Portland, Oregon
    Cancer 98:1417-22. 2003
    ..The objective of the current study was to develop a model for predicting the presence of prostate carcinoma using clinical, laboratory, and transrectal ultrasound (TRUS) data...
  29. ncbi request reprint Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland 97239, Oregon, USA
    Cancer 100:758-63. 2004
    ..The current study evaluated the analgesic activity and impact on quality of life (QOL) of a new chemotherapy regimen of calcitriol and docetaxel in men with androgen-independent prostate carcinoma...
  30. ncbi request reprint Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer
    Tomasz M Beer
    Divisions of Hematology and Medical Oncology, Oregon Health Sciences University and Portland Veterans Affairs Medical Center, Portland, Oregon 97239, USA
    Clin Cancer Res 10:1306-11. 2004
    ..The purpose is to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of mitoxantrone and docetaxel administered weekly before prostatectomy in men with localized prostate cancer at high risk for recurrence...
  31. ncbi request reprint Predictors of delayed therapy after expectant management for localized prostate cancer in the era of prostate-specific antigen
    Irene Panagiotou
    Division of Hematology and Medical Oncology, Cancer Institute, Oregon Health and Science University, Portland, OR, USA
    Oncology 67:194-202. 2004
    ..To identify risk factors for delayed cancer-directed intervention in modern era prostate cancer patients who initially elect expectant management...
  32. ncbi request reprint High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer
    Tomasz M Beer
    Department of Medicine, Oregon Health and Science University, Portland, Oregon 97239, USA
    Am J Clin Oncol 27:535-41. 2004
    ..Despite encouraging preclinical evidence, the addition of oral calcitriol to carboplatin in this study was not associated with an increase in the response rate when compared with the reported activity of carboplatin alone...
  33. ncbi request reprint Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, CR 145, Portland, OR 97239, USA
    Cancer Epidemiol Biomarkers Prev 13:2225-32. 2004
    ..In this study, we selected this approach to test several hypotheses about the effect of calcitriol (1,25-dihydroxycholecalciferol), the active form of vitamin D, on early-stage human prostate cancer...
  34. ncbi request reprint Phase II study of transdermal estradiol in androgen-independent prostate carcinoma
    Lisa B Bland
    Division of Urology, Oregon Health and Science University and Portland Veterans Affairs Medical Center, Portland, Oregon, 97239, USA
    Cancer 103:717-23. 2005
    ..The authors tested the safety and efficacy of transdermal estradiol (TDE), as well as the effect of therapy on hot flashes, sex hormones, the procoagulant cascade, and bone turnover in patients with AIPC...
  35. ncbi request reprint Radical retropubic prostatectomy after orthotopic liver transplantation
    Aaron Bayne
    Division of Urology and Renal Transplantation, Oregon Health and Science University, Portland, Oregon, USA
    Urology 65:175. 2005
    ..In each case, the prostate tumor was organ confined, and both patients were biochemically free of disease at last follow-up...
  36. ncbi request reprint Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer
    Jonathan Q Purnell
    Department of Medicine, Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, OR 97239, USA
    J Lipid Res 47:349-55. 2006
    ..Compared with ADT, short-term TDE therapy of prostate cancer improves lipid levels without deterioration of CVD-associated inflammatory markers and may, on longer-term follow-up, improve CVD and mortality rates...
  37. ncbi request reprint Resistance of prostate cancer cell lines to COX-2 inhibitor treatment
    Matthew Wagner
    Division of Urology and Renal Transplantation, Oregon Health and Science University, Oregon Cancer Institute, Portland, OR, USA
    Biochem Biophys Res Commun 332:800-7. 2005
    ..In conclusion, these studies indicate the lack of a putative role for COX-2 in prostate cancer development. Direct evidence for the involvement of COX-2 in prostate cancer carcinogenesis is desperately needed...
  38. ncbi request reprint A comparison of CT scan to transrectal ultrasound-measured prostate volume in untreated prostate cancer
    S Christopher Hoffelt
    Department of Radiation Oncology, Oregon Health Sciences University, Portland, OR 97239, USA
    Int J Radiat Oncol Biol Phys 57:29-32. 2003
    ..To compare CT and transrectal ultrasound (TRUS)-measured prostate volumes in patients with untreated prostate cancer...
  39. ncbi request reprint Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15
    Chung Ying Huang
    Division of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98105 1024, USA
    Clin Cancer Res 13:5825-33. 2007
    ..To identify molecular alterations associating with in vivo exposure of prostate carcinoma to chemotherapy and assess functional roles modulating tumor response and resistance...
  40. ncbi request reprint Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer
    Matthew Wagner
    Division of Urology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Urology 65:799. 2005
    ..Additional observations are needed to determine whether this is an isolated case or a harbinger of a more common phenomenon...
  41. ncbi request reprint Classification and regression tree analysis for the prediction of aggressive prostate cancer on biopsy
    Stephen E F Spurgeon
    Divisions of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
    J Urol 175:918-22. 2006
    ..Thus, identifying patients who are likely to harbor aggressive cancer could significantly decrease the number of prostate biopsies performed...
  42. ncbi request reprint Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy
    Tomasz M Beer
    Division of Hematology, Oregon Health and Science University, Portland, OR, USA
    J Urol 169:1738-41. 2003
    ..We determine the clinical efficacy of the gonadotropin-releasing hormone (Gn-RH) antagonist abarelix in patients with androgen independent prostate cancer, and measure its effect on serum follicle-stimulating hormone (FSH) and testosterone...
  43. ncbi request reprint Metastatic adenocarcinoma of prostate in a healing sternotomy site
    Greg Adams
    Division of Urology and Renal Transplantation, Oregon Health and Science University, Portland, Oregon, USA
    Urology 68:204.e13-5. 2006
    ....